Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

The Quality Lowdown: Warning Letters, Nitrosamine Recalls And Sen. Warren's Generics Manufacturing Plan

Jan 23 2020

• By Bowman Cox

The Quality Lowdown

Related Content

EU Says Nitrosamine Risk Info Also Needed For New Drug Filings

Jan 13 2020

US FDA Finds Zantac Poses Little Risk, But Concerns Linger

Nov 04 2019

Sticking To Nitrosamine Evaluations Deadline Is Priority For EU Regulators

Dec 09 2019

It’s Time For The Feds To Get Into Drug Manufacturing, Senator Warren Says

Dec 19 2018

Additional Topics

Quality Manufacturing Compliance Enforcement BioPharmaceutical

More from Manufacturing

More from Compliance

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window